Additionally, de novo pyrimidine synthesis has been found to be a targetable vulnerability in diffuse midline gliomas and IDH-mutant gliomas as well as MYC-amplified medulloblastoma, making a compelling argument that targeting DHODH and subsequent epigenetic remodeling could present a new strategy for treating certain undruggable brain cancers [69]. This evidence concerns the gene MYC and medulloblastoma.